New data for Arexvy, GSK’s RSV vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease: London, UK Friday, October 25, 2024, 13:00 Hr ...
Arexvy is currently approved for active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older, and those 50 to 59 years of age who are at increased risk for ...
Visura Technologies, Inc., a privately-held medical device company dedicated to delivering state-of-the-art visualization solutions to improve the safety and success of TEE probe intubations, ...
LSL PHARMA GROUP INC. ("LSL Pharma" or the "Corporation"), an integrated Canadian-based pharmaceutical company, reports that it will make on October 31, 2024, the first interest payment (the "Interest ...